In contrast, in the context of ALK gene fusion positive cancers (2x NSCLC, 1x esophagus, and 1x soft tissue), all recommendations (n = 4) for ALK inhibitors were clinically translated, irrespective of the level of evidence. This evidence concerns the gene ALK and non-small cell lung carcinoma.